The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Fast Company on MSN9d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsSpravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...
The United States Food and Drug Administration (FDA) has approved Spravato (esketamine), a nasal spray from Johnson & Johnson, as a stand-alone therapy for adults with major depressive disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback